Company attributes
Other attributes
Halozyme Therapeutics is a biopharmaceutical company developing products to treat cancer and diabetes that is headquartered in Sand Diego, California and was founded in 1998 by Helen I. Torley.
The following list contains products, collaboration products, and product candidates of Halozyme Therapeutics:
- PEGPH20 with ABRAXANE® (nab-paclitaxel) and gemcitabine
- PEGPH20 with TECENTRIQ® (atezolizumab)
- PEGPH20 with TECENTRIQ® (atezolizumab)
- PEGPH20 with TECENTRIQ® (atezolizumab)
- PEG-ADA2: PEGylated-Human Adenosine Deaminase 2
ENHAZE is the drug delivery technology in development by Halozyme Therapeutics. ENHAZE uses a patented enzyme called recombinant human hyaluronidase PH20 enzyme (rHuPH20) which is capable of locally degrading hyaluronan (HA) in the subcutaneous (SC) space. The ENHAZE enables the increased dispersion and absorption of co-administered therapies.
Halozyme Therapeutics has partnship relationships with the following companies: Roche, Pfizer, Janssen, Baxalta, AbbVie, Eli Lilly, Bristol-Myers Squibb, Alexion, and Argenx. the partnerhsips seek to improve the development of Halozyme Therapeutics ENHANZE drug delivery technology for administrating intravenous biologics and small molecules subcutaneously.
